Notice of extraordinary general meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ), reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9 AM (local time) on Monday 5 March 2018 in the office of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

Senzime proposes directed new issue that includes Segulah Venture AB, amounting to a total of SEK 25 million

Press Release: Uppsala, February 16, 2018. Prior to the commercialization of its products, Senzime AB (publ) (”Senzime” or ”the Company”) is proposing a directed new issue to a few strategically important investors, including Segulah Venture AB, with a maximum of 4,166,667 shares at a subscription price of SEK 6 per share, equivalent to a discount of approximately 8 per cent compared to the share weighted average price of the previous 10 trading days. Through the rights issue, the Company will receive SEK 25 million before issue costs.

Senzime signs cooperation agreement with Philips

Press release; Uppsala, January 23, 2018.  Senzime AB (publ) has signed a license and cooperation agreement with Philips to allow the TetraGraph Neuromuscular Monitoring System to communicate with Philips IntelliVue patient monitors worldwide. 

Press release; Senzime receives CE mark approval for the OnZurf Probe

Uppsala, December 18, 2017. Senzime AB (publ) announces that the company has received CE mark approval for the OnZurf Probe, which means that the product now is approved for sale on the European market.

Press release; Senzime receives CE mark approval for the TetraGraph

Uppsala, December 12, 2017.  Senzime AB (publ) announced today that it has received CE mark approval to enable the commercialization of the TetraGraph Neuromuscular Monitoring System. 

Senzime’s Interim report January – September 2017

Uppsala, November 28, 2017. Senzime AB’s (publ) Interim report for January – September 2017 is now available on the company’s webbsite www.senzime.com.

Comparative Investigation of TetraGraph and TOF-Watch SX

Press release Uppsala, 23 October 2017. Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TetraGraph and TOF-Watch SX. 

Senzime submits 510 (k) application to the FDA

Uppsala, September 25, 2017. Senzime AB (publ) announced today that the company has submitted a 510 (k) application to the US Food and Drug Administration (FDA) for approval of the TetraGraph in the United States. 

Senzime signs distribution agreement for the Swiss market

Uppsala, September 18, 2017. Senzime AB (publ) today announced an exclusive distribution agreement with Leuag AG regarding the Swiss market.

RESOLUTIONS AT SENZIME AB’S (PUBL) EXTRAORDINARY GENERAL MEETING

Senzime AB (publ) (the “Company”) held its Extraordinary General Meeting on September 15, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Notice of Extraordinary General Meeting of Senzime for the introduction of an employee stock option program

Uppsala, August 31, 2017. Senzime AB (publ) calls for an Extraordinary General Meeting for the introduction of an employee stock option program. The Board proposes that the General Meeting approve resolutions to issue no more than 1,300,000 warrants and to introduce an employee stock option plan. 

Senzime’s Interim report January – June 2017

Uppsala, August 31, 2017. Senzime AB’s (publ) Interim report for January – June 2017 is now available on the company’s webbsite www.senzime.com.

Senzime obtains US patent

Uppsala, August 9, 2017. Senzime AB (publ) is awarded a U.S. patent for its TetraSens disposable electrodes. With its unique design, the TetraSens enables fast application and effective function. The electrodes are used in conjunction with Senzime's neuromuscular monitoring system, the TetraGraph, which contributes to effective, continuous monitoring of patients undergoing anesthesia and surgical muscle relaxation. The TetraGraph, via the interfaced TetraSens electrodes, makes it possible to easily and objectively determine the optimal dose of neuromuscular blocking drugs administered during the procedure, and to establish the appropriate time when it is safe to wake the patient after surgery and allow spontaneous breathing without the help of a ventilator. 

TetraGraph clinical use and comparison presented in ASA abstract

Uppsala, 21 June 2017. Senzime AB (publ) in partnership with Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TOF-Watch SX and the TetraGraph. 

Senzime receives ISO 13485 certification

Uppsala, June 12, 2017. Senzime AB (publ) has received ISO 13485 certification, which is an important milestone in the CE labeling process for the company's first monitoring products.

Senzime initiates clinical study with CliniSenz System

Uppsala, May 31, 2017. Senzime AB (publ) initiates a clinical trial with CliniSenz for monitoring of tissue lactate levels after surgery in patients with esophageal cancer, a disease that affects approximately 500,000 patients worldwide annually. The current treatment is mostly surgical with risk of multiple operations and increased mortality. With CliniSenz System, it is possible to monitor the healing process after surgery and detect complications at an early stage. The study has been approved by the Ethics Committee and is expected to start in the beginning of June 2017.

Senzime is granted additional patent for OnZurf Probe

Uppsala, 24 May 2017. Senzime AB’s (publ) application regarding a new Swedish patent for OnZurf Probe has been approved, strengthening Senzime’s existing patent portfolio. The Onzurf Probe is a new generation of microdialysis probes that enable organ-specific biological monitoring of various organs such and the bowel, liver and kidney after surgery. The technology makes it possible to monitor the organs’ healing process and to provide early warning signs of complications such as ischemia and anastomotic failure.

Resolutions at Senzime AB’s (publ) Annual General Meeting

Senzime AB (publ) held its annual general meeting on May 23, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Retransmitting: Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

TetraGraph Functionality in Scientific Abstract at IARS, Washington DC

Uppsala, May 5th, 2017.  Senzime AB (publ) today announced that the scientific abstract, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” is to be presented at the International Anesthesia Research Society (IARS) meeting in Washington, DC where 1200 anesthesiologists participate.

Senzimes first day of trading on Nasdaq First North

Uppsala, April 11, 2017. Senzime AB (publ) recently completed a rights issue that raised SEK 24.4 million before issue costs. Senzime has applied for listing on Nasdaq First North which has been approved with first day of trading April 11, 2017. Previously Senzime was listed on AktieTorget.

Senzime’s rights issue oversubscribed

The subscription period for Senzime AB (publ)’s rights issue with pre-emption rights for existing shareholders (the "Rights Issue") expired on 28 March 2017 and the company is pleased to announce that there has been large interest in the subscription of shares. The Rights Issue was oversubscribed to approximately 103 percent under the original offer. Thus, the company will raise approximately SEK 24.4 million before issue costs, estimated at SEK 3.1 million.

Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North

Uppsala, March 14, 2017. The Board of Senzime AB (publ) ("Senzime") has prepared a prospectus regarding the rights issue that was resolved at the extraordinary general meeting in Senzime on March 3, 2017. The Board of Senzime has also applied for listing on Nasdaq First North, and the first day of trading on Nasdaq First North is expected to be April 11, 2017.

Bulletin from the Extraordinary General Meeting in Senzime AB (publ) – resolution on new issue of shares

The shareholders of Senzime have at the Extraordinary General Meeting on March 3, 2017 resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders. 

1|2|3|4|5